박테리오파지 요법 시장 규모, 점유율, 동향 및 성장 분석 보고서(2026-2034년)

The Bacteriophage Therapy Market size is expected to reach USD 1.84 Billion in 2034 from USD 1.27 Billion (2025) growing at a CAGR of 4.17% during 2026-2034.

The global bacteriophage therapy market is gaining attention as an alternative approach to treating bacterial infections. Bacteriophage therapy uses viruses that specifically target and destroy harmful bacteria without affecting beneficial microorganisms. This treatment method is being explored as a potential solution to antibiotic resistance, which has become a significant global health concern.

Several factors are contributing to the growth of this market. The rising prevalence of antibiotic-resistant infections is encouraging researchers to explore new treatment methods. Bacteriophage therapy offers a targeted approach that may reduce the risk of resistance compared to conventional antibiotics. Additionally, ongoing research and clinical trials are expanding knowledge about the therapeutic potential of bacteriophages.

The future outlook for the bacteriophage therapy market appears promising as interest in alternative antimicrobial treatments increases. Advances in biotechnology and genetic research are expected to improve the effectiveness and safety of bacteriophage therapies. As the medical community continues to search for solutions to antibiotic resistance, bacteriophage therapy may become an important treatment option.

Our reports are meticulously crafted to provide clients with comprehensive and actionable insights into various industries and markets. Each report encompasses several critical components to ensure a thorough understanding of the market landscape:

Market Overview: A detailed introduction to the market, including definitions, classifications, and an overview of the industry's current state.

Market Dynamics: In-depth analysis of key drivers, restraints, opportunities, and challenges influencing market growth. This section examines factors such as technological advancements, regulatory changes, and emerging trends.

Segmentation Analysis: Breakdown of the market into distinct segments based on criteria like product type, application, end-user, and geography. This analysis highlights the performance and potential of each segment.

Competitive Landscape: Comprehensive assessment of major market players, including their market share, product portfolio, strategic initiatives, and financial performance. This section provides insights into the competitive dynamics and key strategies adopted by leading companies.

Market Forecast: Projections of market size and growth trends over a specified period, based on historical data and current market conditions. This includes quantitative analyses and graphical representations to illustrate future market trajectories.

Regional Analysis: Evaluation of market performance across different geographical regions, identifying key markets and regional trends. This helps in understanding regional market dynamics and opportunities.

Emerging Trends and Opportunities: Identification of current and emerging market trends, technological innovations, and potential areas for investment. This section offers insights into future market developments and growth prospects.

MARKET SEGMENTATION

By Targeted Bacteria

• Escherichia coli
• Staphylococcus aureus
• Streptococcus
• Pseudomonas aeruginosa
• Salmonella
• Others

By Disease Indication

• Urinary Tract Infections
• Chronic Otitis
• Dental Extraction
• Chronic Ulcerative Colitis
• Bone Infection
• Wound and Skin Infections
• Cystic Fibrosis
• Others

By Route of Administration

• Oral
• Topical
• Parenteral

By Distribution Channel

• Hospital Pharmacies
• Retail Pharmacies
• Online Pharmacies

COMPANIES PROFILED

• Armata Pharmaceuticals Inc, Adaptive Phage Therapeutics Inc, BiomX Inc, Intralytix Inc, Locus Biosciences Inc, ContraFect Corporation, Micreos BV, Enbiotix Inc, PhagePro Inc, Phagomed Biopharma GmbH, Eligo Bioscience SA, Pherecydes Pharma, Nextbiotics, InnoPhage Ltd, Phi Therapeutics
• We can customise the report as per your requirements.

TABLE OF CONTENTS

Chapter 1. PREFACE

• 1.1. Market Segmentation & Scope
• 1.2. Market Definition
• 1.3. Information Procurement
  • 1.3.1 Information Analysis
  • 1.3.2 Market Formulation & Data Visualization
  • 1.3.3 Data Validation & Publishing
• 1.4. Research Scope and Assumptions
  • 1.4.1 List of Data Sources

Chapter 2. EXECUTIVE SUMMARY

• 2.1. Market Snapshot
• 2.2. Segmental Outlook
• 2.3. Competitive Outlook

Chapter 3. MARKET VARIABLES, TRENDS, FRAMEWORK

• 3.1. Market Lineage Outlook
• 3.2. Penetration & Growth Prospect Mapping
• 3.3. Value Chain Analysis
• 3.4. Regulatory Framework
  • 3.4.1 Standards & Compliance
  • 3.4.2 Regulatory Impact Analysis
• 3.5. Market Dynamics
  • 3.5.1 Market Drivers
  • 3.5.2 Market Restraints
  • 3.5.3 Market Opportunities
  • 3.5.4 Market Challenges
• 3.6. Porter's Five Forces Analysis
• 3.7. PESTLE Analysis

Chapter 4. GLOBAL BACTERIOPHAGE THERAPY MARKET: BY TARGETED BACTERIA 2022-2034 (USD MN)

• 4.1. Market Analysis, Insights and Forecast Targeted Bacteria
• 4.2. Escherichia coli Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 4.3. Staphylococcus aureus Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 4.4. Streptococcus Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 4.5. Pseudomonas aeruginosa Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 4.6. Salmonella Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 4.7. Others Estimates and Forecasts By Regions 2022-2034 (USD MN)

Chapter 5. GLOBAL BACTERIOPHAGE THERAPY MARKET: BY DISEASE INDICATION 2022-2034 (USD MN)

• 5.1. Market Analysis, Insights and Forecast Disease Indication
• 5.2. Urinary Tract Infections Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 5.3. Chronic Otitis Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 5.4. Dental Extraction Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 5.5. Chronic Ulcerative Colitis Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 5.6. Bone Infection Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 5.7. Wound and Skin Infections Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 5.8. Cystic Fibrosis Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 5.9. Others Estimates and Forecasts By Regions 2022-2034 (USD MN)

Chapter 6. GLOBAL BACTERIOPHAGE THERAPY MARKET: BY ROUTE OF ADMINISTRATION 2022-2034 (USD MN)

• 6.1. Market Analysis, Insights and Forecast Route Of Administration
• 6.2. Oral Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 6.3. Topical Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 6.4. Parenteral Estimates and Forecasts By Regions 2022-2034 (USD MN)

Chapter 7. GLOBAL BACTERIOPHAGE THERAPY MARKET: BY DISTRIBUTION CHANNEL 2022-2034 (USD MN)

• 7.1. Market Analysis, Insights and Forecast Distribution Channel
• 7.2. Hospital Pharmacies Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 7.3. Retail Pharmacies Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 7.4. Online Pharmacies Estimates and Forecasts By Regions 2022-2034 (USD MN)

Chapter 8. GLOBAL BACTERIOPHAGE THERAPY MARKET: BY REGION 2022-2034(USD MN)

• 8.1. Regional Outlook
• 8.2. North America Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 8.2.1 By Targeted Bacteria
  • 8.2.2 By Disease Indication
  • 8.2.3 By Route Of Administration
  • 8.2.4 By Distribution Channel
  • 8.2.5 United States
  • 8.2.6 Canada
  • 8.2.7 Mexico
• 8.3. Europe Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 8.3.1 By Targeted Bacteria
  • 8.3.2 By Disease Indication
  • 8.3.3 By Route Of Administration
  • 8.3.4 By Distribution Channel
  • 8.3.5 United Kingdom
  • 8.3.6 France
  • 8.3.7 Germany
  • 8.3.8 Italy
  • 8.3.9 Russia
  • 8.3.10 Rest Of Europe
• 8.4. Asia-Pacific Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 8.4.1 By Targeted Bacteria
  • 8.4.2 By Disease Indication
  • 8.4.3 By Route Of Administration
  • 8.4.4 By Distribution Channel
  • 8.4.5 India
  • 8.4.6 Japan
  • 8.4.7 South Korea
  • 8.4.8 Australia
  • 8.4.9 South East Asia
  • 8.4.10 Rest Of Asia Pacific
• 8.5. Latin America Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 8.5.1 By Targeted Bacteria
  • 8.5.2 By Disease Indication
  • 8.5.3 By Route Of Administration
  • 8.5.4 By Distribution Channel
  • 8.5.5 Brazil
  • 8.5.6 Argentina
  • 8.5.7 Peru
  • 8.5.8 Chile
  • 8.5.9 South East Asia
  • 8.5.10 Rest of Latin America
• 8.6. Middle East & Africa Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 8.6.1 By Targeted Bacteria
  • 8.6.2 By Disease Indication
  • 8.6.3 By Route Of Administration
  • 8.6.4 By Distribution Channel
  • 8.6.5 Saudi Arabia
  • 8.6.6 UAE
  • 8.6.7 Israel
  • 8.6.8 South Africa
  • 8.6.9 Rest of the Middle East And Africa

Chapter 9. COMPETITIVE LANDSCAPE

• 9.1. Recent Developments
• 9.2. Company Categorization
• 9.3. Supply Chain & Channel Partners (based on availability)
• 9.4. Market Share & Positioning Analysis (based on availability)
• 9.5. Vendor Landscape (based on availability)
• 9.6. Strategy Mapping

Chapter 10. COMPANY PROFILES OF GLOBAL BACTERIOPHAGE THERAPY INDUSTRY

• 10.1. Top Companies Market Share Analysis
• 10.2. Company Profiles
  • 10.2.1 Armata Pharmaceuticals Inc
  • 10.2.2 Adaptive Phage Therapeutics Inc
  • 10.2.3 BiomX Inc
  • 10.2.4 Intralytix Inc
  • 10.2.5 Locus Biosciences Inc
  • 10.2.6 ContraFect Corporation
  • 10.2.7 Micreos B.V
  • 10.2.8 Enbiotix Inc
  • 10.2.9 PhagePro Inc
  • 10.2.10 Phagomed Biopharma GmbH
  • 10.2.11 Eligo Bioscience SA
  • 10.2.12 Pherecydes Pharma
  • 10.2.13 Nextbiotics
  • 10.2.14 InnoPhage Ltd
  • 10.2.15 Phi Therapeutics